Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel

Clinical Lymphoma

Volumn 5, Issue 3, 2004, Pages 190-193

  Perna, Ashley G ^a   Jones, Dan M ^b   Duvic, Madeleine ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Bexarotene; CD30; CHOP chemotherapy; Cutaneous T cell lymphoma; Denileukin diftitox; ESHAP chemotherapy; Extranodal non Hodgkin's lymphoma

Indexed keywords

BEXAROTENE; CD30 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; METHYLPREDNISOLONE; PREDNISOLONE; PSORALEN; VINCRISTINE;

ADULT; ANAPLASTIC CARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CAPILLARY LEAK SYNDROME; CASE REPORT; CHILDHOOD DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE DURATION; DYSPNEA; ERYTHEMA; FATIGUE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMATOID PAPULOSIS; MALE; MYALGIA; ONSET AGE; PHOTOTHERAPY; PUSTULE; RARE DISEASE; SKIN BIOPSY; SMALL INTESTINE CANCER; ULTRAVIOLET IRRADIATION;

EID: 13644267440     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2004.n.025     Document Type: Article

References (21)

1. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1) positive lymphoproliferative disorders: a proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 1993; 28:973-980.
2. Demierre MF, Goldberg LJ, Kadin ME, et al. Is it lymphoma or lymphomatoid papulosis? J Am Acad Dermatol 1997; 36:765-772.
3. Karp DL, Horn TD. Lymphomatoid papulosis. J Am Acad Dermatol 1994; 30:379-395.
4. Wang HH, Lach L, Kadin ME. Epidemiology of lymphomatoid papulosis. Cancer 1992; 70:2951-2957.
5. Wang HH, Myers T, Lach LJ, et al. Increased risk of lymphoid and non-lymphoid malignancies in patients with lymphomatoid papulosis. Cancer 1999; 86:1240-1245.
6. Vega F, Medeiros LJ, Jones D, et al. A novel four-color PCR assay to assess T-cell receptor gamma gene rearrangements in lymphoproliferative lesions. Am J Clin Pathol 2001; 116:17-24.
7. Abruzzo LV, Rosales CM, Medeiros LJ, et al. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol 2002; 26:630-636.
8. Van Neer FJ, Toonstra J, Van Voorst Vader PC, et al. Lymphomatoid papulosis in children: a study of 10 children registered by the Dutch Cutaneous Lymphoma Working Group. Br J Dermatol 2001; 144:351-354.
9. Rogers M, de Launey J, Kemp A, et al. Lymphomatoid papulosis in an 11-month-old infant. Pediatr Dermatol 1984; 2:124-130.
10. Zirbel GM, Gellis SE, Kadin ME, et al. Lymphomatoid papulosis in children. J Am Acad Dermatol 1995; 33:741-748.
11. Jaffe ES, Harris NL, Stein H, et al. Pathology and genetics of tumours of the haemopoeitic and lympboid tissues, vol. 3. Lyon, France: International Agency Research Cancer Press, 2001.
12. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and good prognosis and occurs before dissemination. J Clin Pathol 2000; 53:445-450.
13. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al. ALK-negative systemic anaplastic large cell lymphoma: differential diagnosis and prognostic aspects: a review. J Pathol 2003; 200:4-15.
14. Herbst H, Sander C, Tronnier M, et al. Absence of anaplastic lymphoma kinase (ALK) and Epstein-Barr virus gene products in primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis. Br J Dermatol 1997; 137:680-686.
15. Cabanillas F, Armitige J, Pugh WC, et al. Lymphomatoid papulosis: a T-cell dyscrasia with propensity to transform into malignant lymphoma. Ann Intern Med 1995; 122:210-217.
16. Beljaards RC, Willemze R. The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas. Br J Dermatol 1992; 126:596-602.
17. Olsen E, Duvic M, Frankel A, et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19:376-388.
18. Krathen R, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology 2003; 206:142-147.
19. Vonderheid ED, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Ann Acad Dermatol 1996; 34:470-481.
20. Schmuth M, Topar G, Illersperger B, et al. Therapeutic use of interferon-alpha for lymphomatoid papulosis. Cancer 2000; 89:1603-1610.
21. Koon HB, Junghans RP. Anti-CD30 antibody-based therapy. Curr Opin Oncol 2000; 12:588-593.